Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Discover Oncology
Published in: Discover Oncology 1/2023

Open Access 01-12-2023 | Colorectal Cancer | Research

ELFN1-AS1 promotes GDF15-mediated immune escape of colorectal cancer from NK cells by facilitating GCN5 and SND1 association

Authors: Bin Han, Jinsong He, Qing Chen, Min Yuan, Xi Zeng, Yuanting Li, Yan Zeng, Meibo He, Qilin Zhou, Dan Feng, Daiyuan Ma

Published in: Discover Oncology | Issue 1/2023

Login to get access

Abstract

The ability of colorectal cancer (CRC) cells to escape from natural killer (NK) cell immune surveillance leads to anti-tumor treatment failure. The long non-coding RNA (lncRNA) ELFN1-AS1 is aberrantly expressed in multiple tumors suggesting a role as an oncogene in cancer development. However, whether ELFN1-AS1 regulates immune surveillance in CRC is unclear. Here, we determined that ELFN1-AS1 enhanced the ability of CRC cells to escape from NK cell surveillance in vitro and in vivo. In addition, we confirmed that ELFN1-AS1 in CRC cells attenuated the activity of NK cell by down-regulating NKG2D and GZMB via the GDF15/JNK pathway. Furthermore, mechanistic investigations demonstrated that ELFN1-AS1 enhanced the interaction between the GCN5 and SND1 protein and this influenced H3k9ac enrichment at the GDF15 promotor to stimulate GDF15 production in CRC cells. Taken together, our findings indicate that ELFN1-AS1 in CRC cells suppresses NK cell cytotoxicity and ELFN1-AS1 is a potential therapeutic target for CRC.
Appendix
Available only for authorised users
Literature
1.
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;713:209–49.CrossRef
2.
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;662:115–32.CrossRef
3.
Jin J, Tang Y, Hu C, et al. Multicenter, randomized, phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR). J Clin Oncol. 2022;4015:1681–92.CrossRef
4.
Ji D, Song C, Li Y, et al. Combination of radiotherapy and suppression of Tregs enhances abscopal antitumor effect and inhibits metastasis in rectal cancer. J Immunother Cancer. 2020;82:e000826.CrossRef
5.
Jandura A, Krause HM. The new RNA world: growing evidence for long noncoding RNA functionality. Trends Genet. 2017;3310:665–76.CrossRef
6.
Rinn JL, Kertesz M, Wang JK, et al. Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell. 2007;1297:1311–23.CrossRef
7.
Xu F, Hua Q, Zhang A, et al. LncRNA AC020978 facilitates non-small cell lung cancer progression by interacting with malate dehydrogenase 2 and activating the AKT pathway. Cancer Sci. 2021;11211:4501–14.CrossRef
8.
Cao C, Li J, Li G, et al. Long non-coding RNA TMEM220-AS1 suppressed hepatocellular carcinoma by regulating the miR-484/MAGI1 axis as a competing endogenous RNA. Front Cell Dev Biol. 2021;9: 681529.PubMedPubMedCentralCrossRef
9.
Ye GY, Zhang ZZ, Zhu CC, et al. Long non-coding RNA LINC01569 promotes proliferation and metastasis in colorectal cancer by miR-381-3p/RAP2A axis. Front Oncol. 2021;11: 727698.PubMedPubMedCentralCrossRef
10.
Zeng S, Xie X, Xiao YF, et al. Long noncoding RNA LINC00675 enhances phosphorylation of vimentin on Ser83 to suppress gastric cancer progression. Cancer Lett. 2018;412:179–87.PubMedCrossRef
11.
Di Vito C, Calcaterra F, Coianiz N, et al. Natural killer cells in SARS-CoV-2 infection: pathophysiology and therapeutic implications. Front Immunol. 2022;13: 888248.PubMedPubMedCentralCrossRef
12.
Vermijlen D, Luo D, Froelich CJ, et al. Hepatic natural killer cells exclusively kill splenic/blood natural killer-resistant tumor cells by the perforin/granzyme pathway. J Leukoc Biol. 2002;724:668–76.CrossRef
13.
Ran GH, Lin YQ, Tian L, et al. Natural killer cell homing and trafficking in tissues and tumors: from biology to application. Signal Transduct Target Ther. 2022;71:205.CrossRef
14.
Fang P, Xiang L, Chen W, et al. LncRNA GAS5 enhanced the killing effect of NK cell on liver cancer through regulating miR-544/RUNX3. Innate Immun. 2019;252:99–109.CrossRef
15.
Wang Y, Yu G, Liu Y, et al. Hypoxia-induced PTTG3P contributes to colorectal cancer glycolysis and M2 phenotype of macrophage. Biosci Rep. 2021;417.
16.
Li Y, Gan Y, Liu J, et al. Downregulation of MEIS1 mediated by ELFN1-AS1/EZH2/DNMT3a axis promotes tumorigenesis and oxaliplatin resistance in colorectal cancer. Signal Transduct Target Ther. 2022;71:87.CrossRef
17.
Jie Y, Ye L, Chen H, et al. ELFN1-AS1 accelerates cell proliferation, invasion and migration via regulating miR-497-3p/CLDN4 axis in ovarian cancer. Bioengineered. 2020;111:872–82.CrossRef
18.
Zhang C, Lian H, Xie L, Yin N, Cui Y. LncRNA ELFN1-AS1 promotes esophageal cancer progression by up-regulating GFPT1 via sponging miR-183-3p. Biol Chem. 2020;4019:1053–61.CrossRef
19.
Li C, Hong S, Hu H, Liu T, Yan G, Sun D. MYC-induced upregulation of lncRNA ELFN1-AS1 contributes to tumor growth in colorectal cancer via epigenetically silencing TPM1. Mol Cancer Res. 2022.
20.
Lei R, Feng L, Hong D. ELFN1-AS1 accelerates the proliferation and migration of colorectal cancer via regulation of miR-4644/TRIM44 axis. Cancer Biomark. 2020;274:433–43.CrossRef
21.
Zhai LQ, Wang XX, Qu CX, Yang LZ, Jia CM, Shi XC. A long non-coding RNA, ELFN1-AS1, sponges miR-1250 to upregulate MTA1 to promote cell proliferation, migration and invasion, and induce apoptosis in colorectal cancer. Eur Rev Med Pharmacol Sci. 2021;2514:4655–67.
22.
Wu J, Gao FX, Wang C, et al. IL-6 and IL-8 secreted by tumour cells impair the function of NK cells via the STAT3 pathway in oesophageal squamous cell carcinoma. J Exp Clin Cancer Res. 2019;381:321.CrossRef
23.
Han B, Xu K, Feng D, et al. miR-144 inhibits the IGF1R-ERK1/2 signaling pathway via NUDCD1 to suppress the proliferation and metastasis of colorectal cancer cells: a study based on bioinformatics and in vitro and in vivo verification. J Cancer Res Clin Oncol. 2022;1488:1903–18.CrossRef
24.
Fionda C, Scarno G, Stabile H, et al. NK cells and other cytotoxic innate lymphocytes in colorectal cancer progression and metastasis. Int J Mol Sci. 2022;23:7859.PubMedPubMedCentralCrossRef
25.
Yang B, Miao S. lncRNA ELFN1-AS1 predicts poor prognosis and promotes tumor progression of non-small cell lung cancer by sponging miR-497. Cancer Biomark. 2022;344:637–46.CrossRef
26.
Xu F, Li S, Zhang J, et al. Cancer stemness, immune cells, and epithelial–mesenchymal transition cooperatively predict prognosis in colorectal carcinoma. Clin Colorectal Cancer. 2018;173:e579–92.CrossRef
27.
Tabarsa M, Dabaghian EH, You S, et al. Inducing inflammatory response in RAW264.7 and NK-92 cells by an arabinogalactan isolated from Ferula gummosa via NF-kappaB and MAPK signaling pathways. Carbohydr Polym. 2020;241:116358.PubMedCrossRef
28.
Yang C, Qian C, Zhang T, et al. The killing effect of Tanshinol on breast cancer cells: insight into the reversion of TGF-beta1-mediated suppression of NK cell functions. Front Biosci (Landmark Ed). 2021;2611:1106–18.
29.
Linhares ND, Pereira DA, Conceicao IM, et al. Noncoding SNPs associated with increased GDF15 levels located in a metformin-activated enhancer region upstream of GDF15. Pharmacogenomics. 2020;218:509–20.CrossRef
30.
Xin L, Zhao R, Lei J, et al. SND1 acts upstream of SLUG to regulate the epithelial-mesenchymal transition (EMT) in SKOV3 cells. FASEB J. 2019;333:3795–806.CrossRef
31.
Lv Y, Lv Y, Wang Z, Yuan K, Zeng Y. Noncoding RNAs as sensors of tumor microenvironmental stress. J Exp Clin Cancer Res. 2022;411:224.CrossRef
32.
Ashrafizadeh M, Zarrabi A, Mostafavi E, et al. Non-coding RNA-based regulation of inflammation. Semin Immunol. 2022;59:101606.PubMedCrossRef
33.
Chao HM, Wang TW, Chern E, Hsu SH. Regulatory RNAs, microRNA, long-non coding RNA and circular RNA roles in colorectal cancer stem cells. World J Gastrointest Oncol. 2022;144:748–64.CrossRef
34.
Piper M, Van Court B, Mueller A, et al. Targeting Treg-expressed STAT3 enhances NK-mediated surveillance of metastasis and improves therapeutic response in pancreatic adenocarcinoma. Clin Cancer Res. 2022;285:1013–26.CrossRef
35.
Menyailo ME, Bokova UA, Ivanyuk EE, Khozyainova AA, Denisov EV. Metastasis prevention: focus on metastatic circulating tumor cells. Mol Diagn Ther. 2021;255:549–62.CrossRef
36.
Liu Y, Cao X. Immunosuppressive cells in tumor immune escape and metastasis. J Mol Med (Berl). 2016;945:509–22.CrossRef
37.
Ferguson Bennit HR, Gonda A, Kabagwira J, et al. Natural killer cell phenotype and functionality affected by exposure to extracellular survivin and lymphoma-derived exosomes. Int J Mol Sci. 2021;22:1255.PubMedPubMedCentralCrossRef
38.
Sumi D, Tsuyama H, Ogawa T, Ogawa M, Himeno S. Arsenite suppresses IL-2-dependent tumoricidal activities of natural killer cells. Toxicol Appl Pharmacol. 2021;412: 115353.PubMedCrossRef
39.
Luo K, Song Y, Guan Z, et al. A KRAS-associated signature for prognostic, immune and chemical anti-cancer drug-response prediction in colon cancer. Front Pharmacol. 2022;13: 899725.PubMedPubMedCentralCrossRef
40.
Lanuza PM, Alonso MH, Hidalgo S, et al. Adoptive NK Cell transfer as a treatment in colorectal cancer patients: analyses of tumour cell determinants correlating with efficacy in vitro and in vivo. Front Immunol. 2022;13: 890836.PubMedPubMedCentralCrossRef
41.
Bottos A, Gotthardt D, Gill JW, et al. Decreased NK-cell tumour immunosurveillance consequent to JAK inhibition enhances metastasis in breast cancer models. Nat Commun. 2016;7:12258.PubMedPubMedCentralCrossRef
42.
Putz EM, Gotthardt D, Hoermann G, et al. CDK8-mediated STAT1-S727 phosphorylation restrains NK cell cytotoxicity and tumor surveillance. Cell Rep. 2013;43:437–44.CrossRef
43.
Ji J, Yin Y, Ju H, et al. Long non-coding RNA Lnc-Tim3 exacerbates CD8 T cell exhaustion via binding to Tim-3 and inducing nuclear translocation of Bat3 in HCC. Cell Death Dis. 2018;95:478.CrossRef
44.
Wang P, Xue Y, Han Y, et al. The STAT3-binding long noncoding RNA lnc-DC controls human dendritic cell differentiation. Science. 2014;3446181:310–3.CrossRef
45.
Kim T, Jeon YJ, Cui R, et al. Role of MYC-regulated long noncoding RNAs in cell cycle regulation and tumorigenesis. J Natl Cancer Inst. 2015;107(4).
46.
Tan P, Chen H, Huang Z, et al. MMP25-AS1/hsa-miR-10a-5p/SERPINE1 axis as a novel prognostic biomarker associated with immune cell infiltration in KIRC. Mol Ther Oncolytics. 2021;22:307–25.PubMedPubMedCentralCrossRef
47.
Zhou J, Valentini E, Boutros M. Microenvironmental innate immune signaling and cell mechanical responses promote tumor growth. Dev Cell. 2021;5613(1884–99): e5.
48.
Song H, Park H, Kim J, et al. IDO metabolite produced by EBV-transformed B cells inhibits surface expression of NKG2D in NK cells via the c-Jun N-terminal kinase (JNK) pathway. Immunol Lett. 2011;1362:187–93.CrossRef
49.
Li C, Ge B, Nicotra M, et al. JNK MAP kinase activation is required for MTOC and granule polarization in NKG2D-mediated NK cell cytotoxicity. Proc Natl Acad Sci USA. 2008;1058:3017–22.CrossRef
50.
51.
Tabarsa M, You S, Yelithao K, Palanisamy S, Prabhu NM, Nan M. Isolation, structural elucidation and immuno-stimulatory properties of polysaccharides from Cuminum cyminum. Carbohydr Polym. 2020;230: 115636.PubMedCrossRef
52.
Kumar D, Hosse J, von Toerne C, Noessner E, Nelson PJ. JNK MAPK pathway regulates constitutive transcription of CCL5 by human NK cells through SP1. J Immunol. 2009;1822:1011–20.CrossRef
53.
Zhang HG, Grizzle WE. Exosomes: a novel pathway of local and distant intercellular communication that facilitates the growth and metastasis of neoplastic lesions. Am J Pathol. 2014;1841:28–41.CrossRef
54.
Crane CA, Han SJ, Barry JJ, Ahn BJ, Lanier LL, Parsa AT. TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients. Neuro Oncol. 2010;121:7–13.CrossRef
55.
Li L, Zhang R, Yang H, et al. GDF15 knockdown suppresses cervical cancer cell migration in vitro through the TGF-beta/Smad2/3/Snail1 pathway. FEBS Open Bio. 2020;1012:2750–60.CrossRef
56.
Kleinertz H, Hepner-Schefczyk M, Ehnert S, et al. Circulating growth/differentiation factor 15 is associated with human CD56(bright) natural killer cell dysfunction and nosocomial infection in severe systemic inflammation. EBioMedicine. 2019;43:380–91.PubMedPubMedCentralCrossRef
57.
Roth P, Junker M, Tritschler I, et al. GDF-15 contributes to proliferation and immune escape of malignant gliomas. Clin Cancer Res. 2010;1615:3851–9.CrossRef
58.
Chaudhry K, Dowlati E, Long MD, et al. Comparable transforming growth factor beta-mediated immune suppression in ex vivo-expanded natural killer cells from cord blood and peripheral blood: implications for adoptive immunotherapy. Cytotherapy. 2022;248:802–17.CrossRef
59.
Li S, Ma YM, Zheng PS, Zhang P. GDF15 promotes the proliferation of cervical cancer cells by phosphorylating AKT1 and Erk1/2 through the receptor ErbB2. J Exp Clin Cancer Res. 2018;371:80.CrossRef
60.
Lu X, He X, Su J, et al. EZH2-mediated epigenetic suppression of GDF15 predicts a poor prognosis and regulates cell proliferation in non-small-cell lung cancer. Mol Ther Nucleic Acids. 2018;12:309–18.PubMedPubMedCentralCrossRef
61.
Ho CM, Donovan-Banfield IZ, Tan L, Zhang T, Gray NS, Strang BL. Inhibition of IKKalpha by BAY61-3606 reveals IKKalpha-dependent histone H3 phosphorylation in human cytomegalovirus infected cells. PLoS ONE. 2016;113: e0150339.CrossRef
62.
Dong J, He J, Zhang Z, et al. Identification of lysine acetylome of oral squamous cell carcinoma by label-free quantitative proteomics. J Proteomics. 2022;262: 104598.PubMedCrossRef
63.
Yu L, Di Y, Xin L, et al. SND1 acts as a novel gene transcription activator recognizing the conserved Motif domains of Smad promoters, inducing TGFbeta1 response and breast cancer metastasis. Oncogene. 2017;3627:3903–14.CrossRef
64.
Lee HS, Park JH, Kim SJ, Kwon SJ, Kwon J. A cooperative activation loop among SWI/SNF, gamma-H2AX and H3 acetylation for DNA double-strand break repair. EMBO J. 2010;298:1434–45.CrossRef
65.
Fu X, Zhang C, Meng H, et al. Oncoprotein Tudor-SN is a key determinant providing survival advantage under DNA damaging stress. Cell Death Differ. 2018;259:1625–37.CrossRef
66.
Wang W, Huang P, Dai W, et al. Application of nicotinamide to culture medium improves the efficiency of genome editing in hexaploid wheat. Int J Mol Sci. 2023;24:4416.PubMedPubMedCentralCrossRef
67.
Xiang JF, Yin QF, Chen T, et al. Human colorectal cancer-specific CCAT1-L lncRNA regulates long-range chromatin interactions at the MYC locus. Cell Res. 2014;245:513–31.CrossRef
68.
Zhang KL, Zhu WW, Wang SH, et al. Organ-specific cholesterol metabolic aberration fuels liver metastasis of colorectal cancer. Theranostics. 2021;1113:6560–72.CrossRef
Metadata
Title
ELFN1-AS1 promotes GDF15-mediated immune escape of colorectal cancer from NK cells by facilitating GCN5 and SND1 association
Authors
Bin Han
Jinsong He
Qing Chen
Min Yuan
Xi Zeng
Yuanting Li
Yan Zeng
Meibo He
Qilin Zhou
Dan Feng
Daiyuan Ma
Publication date
01-12-2023
Publisher
Springer US
Published in
Discover Oncology / Issue 1/2023
Print ISSN: 1868-8497
Electronic ISSN: 2730-6011
DOI
https://doi.org/10.1007/s12672-023-00675-6

Other articles of this Issue 1/2023

Discover Oncology 1/2023 Go to the issue

Research

Myc derived circRNA promotes triple-negative breast cancer progression via reprogramming fatty acid metabolism

Research

Activating the Hippo pathway by nevadensin overcomes Yap-drived resistance to sorafenib in hepatocellular carcinoma

Research

Novel diagnostic biomarkers of oxidative stress, immune- infiltration characteristics and experimental validation of SERPINE1 in colon cancer

Research

Using machine learning-based radiomics to differentiate between glioma and solitary brain metastasis from lung cancer and its subtypes

Correction

Correction: The relationship of serum gastrin-17 and oral mucositis in head and neck carcinoma patients receiving radiotherapy

Research

The role of pyroptosis-related lncRNA risk signature in ovarian cancer prognosis and immune system
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits